Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery.

Yang XR, Xu Y, Yu B, Zhou J, Li JC, Qiu SJ, Shi YH, Wang XY, Dai Z, Shi GM, Wu B, Wu LM, Yang GH, Zhang BH, Qin WX, Fan J.

Clin Cancer Res. 2009 Sep 1;15(17):5518-27. doi: 10.1158/1078-0432.CCR-09-0151. Epub 2009 Aug 25.

2.

Surgical treatment of hepatocellular carcinoma and related basic research with special reference to recurrence and metastasis.

Tang Z, Zhou X, Lin Z, Yang B, Ma Z, Ye S, Wu Z, Fan J, Liu Y, Liu K, Qin L, Tian J, Sun H, He B, Xia J, Qiu S, Zhou J.

Chin Med J (Engl). 1999 Oct;112(10):887-91. Review.

PMID:
11717970
3.

Prognostic significance of pathological and biological factors in hepatocellular carcinoma.

Ng IO.

J Gastroenterol Hepatol. 1998 Jun;13(6):666-70. Review.

PMID:
9715414
4.

Recent advances in tumor markers of human hepatocellular carcinoma.

Yoon SK.

Intervirology. 2008;51 Suppl 1:34-41. doi: 10.1159/000122596. Epub 2008 Jun 10. Review.

PMID:
18544946
5.

Specific molecular markers in hepatocellular carcinoma.

Yao DF, Dong ZZ, Yao M.

Hepatobiliary Pancreat Dis Int. 2007 Jun;6(3):241-7. Review.

PMID:
17548245
6.

[Prevention of recurrent hepatocellular carcinoma with retinoid].

Moriwaki H.

Gan To Kagaku Ryoho. 2001 Dec;28(13):1980-4. Review. Japanese.

PMID:
11791378
7.
8.

[Diagnosis of tumours of the liver and the biliary tract: new tissue and serum markers].

Riener MO.

Pathologe. 2011 Nov;32 Suppl 2:304-9. doi: 10.1007/s00292-011-1467-6. Review. German.

PMID:
21814862
9.

[Hepatocarcinogenesis in human liver].

Nagy P, László V, Schaff Z.

Magy Onkol. 2006;50(2):107-13. Epub 2006 Aug 4. Review. Hungarian.

10.

Proteomics for the early detection and treatment of hepatocellular carcinoma.

Feng JT, Shang S, Beretta L.

Oncogene. 2006 Jun 26;25(27):3810-7. Review.

PMID:
16799622
11.

Histone deacetylase inhibitors for treatment of hepatocellular carcinoma.

Coradini D, Speranza A.

Acta Pharmacol Sin. 2005 Sep;26(9):1025-33. Review.

12.

[Hepatocellular carcinoma: tumoral or peritumoral disease?].

Giannelli G, Antonaci S.

Recenti Prog Med. 2007 Jan;98(1):23-8. Review. Italian.

PMID:
17345877
13.

Hepatocellular carcinoma in Keio affiliated hospitals--diagnosis, treatment, and prognosis of this disease.

Saito H, Masuda T, Tada S, Ebinuma H, Yamagishi Y, Ojiro K, Inoue M, Hibi T.

Keio J Med. 2009 Sep;58(3):161-75. Review.

14.

Molecular aspects of hepatocellular carcinoma.

Abou-Shady M, Baer HU, Friess H, Zimmermann A, Büchler MW.

Swiss Surg. 1999;5(3):102-6. Review.

PMID:
10414179
15.

Biological treatment for liver tumor and new potential biomarkers.

Chiriva-Internati M, Grizzi F, Wachtel MS, Jenkins M, Ferrari R, Cobos E, Frezza EE.

Dig Dis Sci. 2008 Mar;53(3):836-43. Epub 2007 Aug 22. Review.

PMID:
17712633
16.

CD24 and human carcinoma: tumor biological aspects.

Lim SC.

Biomed Pharmacother. 2005 Oct;59 Suppl 2:S351-4. Review.

PMID:
16507407
17.

Clinical staging of hepatocellular carcinoma.

Meier V, Ramadori G.

Dig Dis. 2009;27(2):131-41. doi: 10.1159/000218345. Epub 2009 Jun 22. Review.

PMID:
19546551
18.

Translational microarray systems for outcome prediction of hepatocellular carcinoma.

Iizuka N, Hamamoto Y, Tsunedomi R, Oka M.

Cancer Sci. 2008 Apr;99(4):659-65. doi: 10.1111/j.1349-7006.2008.00751.x. Review.

19.

The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: from research to therapy.

Sagiv E, Arber N.

Expert Rev Gastroenterol Hepatol. 2008 Feb;2(1):125-33. doi: 10.1586/17474124.2.1.125. Review.

PMID:
19072375
20.

Tissue biomarkers of prognostic significance in hepatocellular carcinoma.

Pinato DJ, Pirisi M, Maslen L, Sharma R.

Adv Anat Pathol. 2014 Jul;21(4):270-84. doi: 10.1097/PAP.0000000000000029. Review.

PMID:
24911252

Supplemental Content

Support Center